BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23681790)

  • 1. [Antipsychotic polypharmacy in high-utilising patients with schizophrenia].
    Schmidt-Kraepelin C; Puschner B; Loos S; Janssen B
    Psychiatr Prax; 2013 Oct; 40(7):380-4. PubMed ID: 23681790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
    Cook B; Hoogenboom G
    Australas Psychiatry; 2004 Mar; 12(1):74-6. PubMed ID: 15715745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.
    Honer WG; Procyshyn RM; Chen EY; MacEwan GW; Barr AM
    J Psychiatry Neurosci; 2009 Nov; 34(6):433-42. PubMed ID: 19949719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging guidelines for the use of antipsychotic polypharmacy.
    Stahl SM
    Rev Psiquiatr Salud Ment; 2013; 6(3):97-100. PubMed ID: 23485567
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
    Velligan DI; Carroll C; Lage MJ; Fairman K
    Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
    Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
    JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
    Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
    Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
    Zink M; Knopf U; Henn FA; Thome J
    Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
    Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
    J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of treatment resistant schizophrenia unresponsive to clozapine.
    Barnes TR; McEvedy CJ; Nelson HE
    Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653
    [No Abstract]   [Full Text] [Related]  

  • 16. Clozapine-associated asterixis: case report.
    Kwak YT; Yang Y; Koo MS
    J Clin Psychopharmacol; 2014 Feb; 34(1):165-7. PubMed ID: 24158019
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].
    Gazdag G; Tolna J; Bitter I
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):189-95. PubMed ID: 22987732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients.
    Schneider AL; Mosier KE; Tempier RP
    J Clin Psychiatry; 2009 Jun; 70(6):937-9. PubMed ID: 19573492
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 20. Polypharmacy in schizophrenia.
    Zink M; Englisch S; Meyer-Lindenberg A
    Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.